[1] I. A. Khan, S. Siddiqui and S. Rehmani, Fluoroquinolones inhibit HCV by targeting its helicase. Antivir. Ther., 17 (2012) 467-476.
[2] B. C. Smith and J. M. Denu, Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta, 17 (2009) 45-57.
[3] M. J. Lai, H. L. Huang and S. L. Pan, Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide) indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 55 (2012) 3777-3791.
[4] F. F. Wagner, D. E. Olson, and J. P. Gale, Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. J. Med. Chem., 56 (2013) 1772-1776.
[5] H. Y. Lee, A. C. Tsai and M. C. Chen, Azaindolyl sulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. J. Med. Chem., 57 (2014) 4009-4022.
[6] C. Tang, C. H. Li and S. L. Zhang, Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer. J. Med. Chem., 58 (2015) 4550-4572.
[7] Y. W. Yao, H. Q. Yao and S. Jiang, Progress in clinical study of histone deacetylases inhibitors as anticancer agents .Chin. J. New. Drugs., 22 (2013) 294-299.
[8] P. Guan, X. Hou and L. Wang, Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. Bioorg. Med. Chem., 22 (2014) 5766−5775.
[9] Y. M. Tan, W. Y. Huang and N. F. Yu, Structure-activity relationships of histone deacetylase inhibitors. Acta Pharm. Sin., 44 (2009) 1072-1083.
[10] S. Q. Xie, and Y. S. Chen, Part IV. Synthesis and antitumor evaluation of s-triazolothiadiazines and pyrazolos-triazoles derived from criproxacin. Acta Pharm. Sin., 47 (2012) 66-71.
[11] L. Z. Gao Y. S. Xie and T. Li, Synthesis, antitumor activity and SAR of C-3 oxadiazole sulfanylacetyl hydrazone-substituted fluoroquinolone analogues. Acta Pharm. Sin., 49 (2014) 1694-1698.
[12] Y. Itoh, and T. Suzuki, Isoform-selective histonedeacetylase inhibitors. Curr. Pharm. Des., 14 (2008) 529-544.
[13] J. Senger, J. Melesina and M. Marek, Synthesis and biological investigation of oxazole hydroxamatesas highly selective histone deacetylase 6 (HDAC6) inhibitors. J. Med. Chem., 59 (2016) 1545-1555.
[14] J. K. Murray and C. Balan, Dipeptidylquinolone derivatives inhibit hypoxia inducible factor-1 prolyl hydroxylases-1, -2, and -3 with altered selectivity. J. Comb. Chem., 12 (2010) 676-686.
[15] X. L. Jiang, Y. B. Cui and S. H. Cao, Progress in research on quinolone antibacterials. Chin. J. Antibiot., 36 (2011) 255-263.
[16] H. Li, X. Han and D. W. Li, Synthesis and anti-tumor activity of levofloxacin-thiadiazole histone deacetylase inhibitor conjugates. Acta Pharm. Sinica, 52 (2017) 582-591.
[17] L. B. Kier and L. H. Hall, An electrotopological-state index for atoms in molecules. Pharm. Res., 7 (1990) 801-807.